Widespread use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in heart failure patients has strengthened the role of SPECT and PET in developing, optimizing and personalizing treatment of the condition, according to experts in the field and a series of recent studies. "If you use imaging appropriately before the transition to end-stage cardiomyopathy occurs, patient lifestyle is better, morbidity and mortality is better and the health care costs downstream will be better," said Dr. Vasken Dilsizian, whose work has explored the use of imaging in determining who might benefit from treatment with ACE inhibitors. "Everyone looks at the bottom line rather than the consequences. [The Affordable Care Act] is addressing prevention, and imaging is part of that, especially in heart failure patients."

Related Summaries